Scope
The ACG coeliac disease update covers diagnosis, gluten-free dietary treatment and lifelong follow-up in children and adults. It prioritizes testing during gluten exposure, biopsy confirmation for most patients and carefully selected non-biopsy pathways. Long-term care goes beyond symptom control: dietitian support, nutritional recovery, preventive care and assessment of persistent symptoms are central. Recommendations and key concepts are distinguished where evidence is conditional or incomplete.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identify candidates and test while eating gluten
- ACG strongly recommends active case finding for coeliac disease and recommends against community-wide mass screening, with low-quality evidence. A separate ungraded key concept advises testing people with malabsorptive symptoms or laboratory abnormalities, including chronic diarrhoea with weight loss, steatorrhoea, abdominal pain or bloating. [1]
- Ask about a first-degree relative with confirmed coeliac disease and consider testing asymptomatic first-degree relatives as well. Unexplained elevated liver enzymes warrant assessment for coeliac disease. [1]
- Measure tissue-transglutaminase IgA while the patient is eating a gluten-containing diet, alongside total IgA if IgA deficiency has not previously been excluded. If IgA deficiency is present, use IgG-based serology. Do not interpret testing after gluten avoidance as equivalent to testing on a regular diet. [1]
- For children younger than 2 years who are not IgA-deficient, TTG-IgA is the preferred single test. For IgA-deficient children, use DGP-IgG or TTG-IgG. ACG gives both recommendations strong support with moderate-quality evidence. [1]
Confirm the diagnosis before lifelong dietary treatment
- ACG strongly recommends upper gastrointestinal endoscopy with multiple duodenal biopsies to confirm suspected coeliac disease in children and adults. Obtain 1–2 bulb specimens and 4 distal duodenal specimens. [1]
- In selected children, TTG-IgA above 10 times the upper limit of normal plus positive endomysial antibody in a second blood sample can support a non-biopsy diagnosis when the family agrees. This is a conditional recommendation, not a replacement for biopsy in every child. [1]
- In symptomatic adults unable or unwilling to undergo endoscopy, TTG-IgA above 10 times the upper limit of normal plus positive endomysial antibody in a second blood sample may support an after-the-fact diagnosis of likely coeliac disease. Retain the distinction between likely disease and biopsy-confirmed disease. [1]
- A negative antibody result does not end the investigation when clinical suspicion is high: consider endoscopy with duodenal biopsy. Conversely, isolated lymphocytic duodenosis without villous atrophy is not specific for coeliac disease and requires consideration of other causes. [1]
- HLA testing is not required routinely, but can help resolve serology–histology disagreement or evaluate someone already on a gluten-free diet. A negative compatible-haplotype test rules out coeliac disease; a compatible result can support offering a gluten challenge when prior dietary restriction has obscured diagnosis. [1]
Support a sustainable gluten-free diet
- Treat confirmed coeliac disease with a strict gluten-free diet and lifelong medical follow-up. Arrange a dietitian assessment after diagnosis, with further visits to reinforce understanding and adherence. [1]
- Include gluten-free oats if tolerated, while monitoring for contamination, variable oat toxicity or an immune response to avenin. This is a strong recommendation with moderate-quality evidence; it does not mean every oat product is safe or tolerated. [1]
- Assess dietary adherence through an interview with a dietitian experienced in gluten-free diets. ACG conditionally advises against routine food, urine or stool gluten-detection devices; these may not distinguish clinically important exposure from trivial exposure. [1]
- Do not present probiotics as established coeliac treatment: evidence is insufficient to recommend either for or against them. They cannot replace the dietary treatment described in this guideline. [1]
Monitor recovery and preventive care
- Discuss intestinal healing as a treatment goal beyond symptom relief and serological normalization. ACG makes this a conditional recommendation with low-quality evidence and calls for individualized discussion with the patient. [1]
- Upper endoscopy with intestinal biopsies can help when symptoms fail to improve or recur despite dietary treatment. In an asymptomatic adult, a follow-up biopsy after 2 years of a gluten-free diet can be considered through shared decision making. [1]
- Do not routinely perform follow-up biopsy in an asymptomatic child adhering to a gluten-free diet. Growth and development should be part of paediatric monitoring. [1]
- Individualize follow-up blood testing to confirm correction of abnormalities present at diagnosis. Symptom improvement and negative serology do not by themselves establish intestinal healing. [1]
- Consider pneumococcal vaccination in coeliac disease; ACG’s recommendation is conditional with low-quality evidence. Select the vaccination regimen using the patient’s age, previous immunizations and comorbidity. [1]
Investigate persistent symptoms systematically
- When symptoms persist or recur, review the original diagnosis and assess inadvertent gluten exposure with expert dietary review and serology. Depending on the clinical presentation, evaluate functional disorders, lactose or fructose intolerance, pancreatic insufficiency, microscopic colitis and small-intestinal bacterial overgrowth. [1]
- Do not label symptoms alone as refractory disease. Refractory coeliac disease requires persistent or recurrent malabsorptive symptoms and villous atrophy despite a strict gluten-free diet for more than 12 months, after excluding other disorders including overt lymphoma. Specialist assessment distinguishes abnormal or clonal intestinal lymphocyte populations. [1]
Limitations and use
- This summary does not specify a gluten-challenge regimen, a complete nutrient-replacement schedule or treatment regimens for refractory disease.
- Pneumococcal vaccine products and schedules depend on current local recommendations; the guideline’s historical US schedule is not reproduced as a current Indian schedule.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diagnosis and Management of Celiac Disease
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.